Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia

NCT01253070 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01253070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01253070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2011
Completion date
April 15, 2021
Enrollment
54 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with flt3/itd mutation, acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); cbfb-myh11, acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, acute promyelocytic leukemia with pml-rara, flt3 gene mutation, therapy-related acute myeloid leukemia